Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MucoMilk for Prevention of C. difficile-associated Diarrhea Relapse
NCT00177775Phase 3Terminated
- Sponsor
- University of Pittsburgh
- Start
- Apr 2005
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of MucoMilk in Clostridium difficile infection (CDI) (2 arms), sponsored by University of Pittsburgh. Primary endpoint: Safety of MucoMilk at Day 60. Started Apr 2005; status: terminated.
02
Drugs
MucoMilk
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT00177775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177775.